Coya Therapeutics, Inc. (COYA)

NCM – Real Time Price. Currency in USD

4.72

-0.07 (-1.56%)

Market open: Aug 12, 2026, 2:27 PM EDT

4.88

+0.08 (1.58%)

Previous after-hours: Aug 11, 2026, 6:30 PM EDT

11.08.2026

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update. “During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. “E.

Videos

No Data

There is no data to display

Press releases

11.08.2026

Coya Therapeutics, Inc. (COYA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Coya Therapeutics, Inc. (COYA)

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Videos

No Data

Press releases

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Videos

No Data

Press releases

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Search stocks

Coya Therapeutics, Inc. (COYA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Coya Therapeutics, Inc. (COYA)

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Videos

No Data

Press releases

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Videos

No Data

Press releases

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update